Mologic Receives CE Mark Approval for BVPro Point-of-Care Diagnostic for Patients with Bacterial Vaginosis

Tuesday, September 19, 2017

Mologic Ltd, which develops powerful, personalised diagnostics to improve the lives of patients, today announced it has received CE mark approval for BVPro®, a rapid point-of-care test for patients presenting with symptoms of vaginosis. The Company also announced the commercial launch of the test, and that it has signed a 3-year distribution agreement with Hitado GmbH, a leading diagnostic supplier specialising in point of care products, and subsidiary of Sysmex, to enable distribution of BVPro throughout Germany.

Bacterial vaginosis (BV) is an abnormal vaginal condition that is characterised by vaginal discharge and results from an overgrowth of atypical bacteria in the vagina. Although not critical in its own right, BV is associated with serious medical complications such as post-operative infections, a greater susceptibility of contracting sexually transmitted infections (STIs) such as genital herpes and HIV, and also a higher risk of preterm birth in pregnant women.

BVPro is a simple, 15-minute, point-of-care diagnostic for professional use with patients presenting with symptoms of vaginosis. It detects sialidase enzyme activity from a vaginal swab sample which is a well-established clinical marker of bacterial vaginosis. The CE marked diagnostic has been designed in the familiar lateral flow format (typical of pregnancy tests) so that the visual result is easy to interpret and enables a rapid, alternative to current methods, such as wet mount microscopic analysis and test tube-based colour-change assays, which often provide ambiguous results and are time consuming.

Mark Davis, co-founder and CEO at Mologic commented: “BVPro is another in Mologic’s pipeline of diagnostic tests to receive CE mark approval. We are very pleased to be making such progress in bringing point of care tests to patients and by doing so, enabling the earlier treatment of a range of diseases, including sepsis, urinary tract infections and chronic obstructive pulmonary disease (COPD). Appointing Hitado to distribute our products in Germany represents a significant milestone for our company; we look forward to working with them as our first formal distributor and also others as we bring them on board in different geographies.

To find out more about BVPro visit: https://mologic.co.uk/bvpro/

Notes to Editors

For a high resolution image please contact sarah.jeffery@zymecommunications.com

Media contact:
For more information please contact:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730919

About Mologic www.mologic.co.uk

Mologic Ltd develops powerful, personalised diagnostics to improve the lives of patients. With a scientific team expert in translating science into practical solutions, the Company delivers technology where it is needed, to improve patient care and quality of life, breaking new ground in exciting fields of research. Mologic is focused on collaboration, partnerships and diversity and its   innovative approach has generated an advanced portfolio of accurate and reliable point of care diagnostic tools for a variety of conditions, including COPD, diabetes, sepsis, UTIs, malignancies, inflammatory and respiratory conditions, and renal disease.

Led by co-founders Paul Davis, CSO, and Mark Davis, CEO, the Company’s broad range of skills and experience covers services from innovation to manufacture, including molecular engineering, assay and reagent development, clinical evaluation, antibodies, research and IP. Mologic’s low-volume manufacturing facility (ISO13485 certified) enables the business to take on almost any project challenge, irrespective of size, complexity or stage. Through professional partnerships, products have achieved high volume manufacturing, distribution and regulatory support globally.

Mologic’s interests extend beyond human healthcare, with active programs in agricultural diagnostics, large animal studies and vaccine innovation, successfully translating their advances in patient technology to other sectors

About Hitado GmbH www.hitado.de

Hitado was founded 44 years ago as a provider of laboratory diagnostics for hospitals and laboratories. Today, it is part of the Sysmex Group, a global leader in in vitro diagnostics.

Hitado is a leading provider of patient immediate diagnosis with a wide range of highly specific rapid tests from a wide range of applications such as cancer screening, cardiac diagnostics, pregnancy, infection and metabolism diagnostics, to POCT system solutions for professional users in the residential and hospital sectors. Its products are all tested and meet all requirements for in vitro diagnostics.

Hitado offers high-quality services and services from a single source - including consulting, installation and support.